Genomic characterization of different visceral metastatic patterns in prostate cancer patients
-
摘要: 目的 揭示不同内脏转移模式的前列腺癌患者临床特征与基因组突变模式的差异。方法 通过对复旦大学附属肿瘤医院前列腺癌前瞻性临床基因组队列中的859例患者进行分析，本研究筛选出75例内脏转移患者，其中肺转移41例，肝转移34例。所有患者均有统一完善的临床及基因组学信息。本研究对肺转移与肝转移两类转移模式与前列腺癌患者发病年龄、病理特征、疾病侵袭性等临床特征，以及重要驱动基因变异之间的关联进行了统计学分析。结果 肺转移和肝转移在转移性去势敏感性前列腺癌中的发生率分别为9.3%和3.0%，转移性去势抵抗性前列腺癌的发生率分别为6.2%和9.1%。肺转移和肝转移前列腺癌在发病年龄、前列腺特异性抗原水平、Gleason评分等临床特征上并无显著性差异。但在基因层面，肝转移患者表现出更高的AR(38.2% vs 12.2%，P=0.013)和CCND1(20.6% vs 2.4%，P=0.02)拷贝数扩增频率、PTEN(20.6% vs 2.4%，P=0.02)和BRCA2(11.8% vs 0%，P=0.04)拷贝数缺失频率。结论 转移性去势敏感期患者应重视肺转移的筛查，而对于去势抵抗期患者更应该警惕肝转移发生的可能。尽管当前不同内脏转移前列腺癌患者适用同一套治疗策略与标准，但关键驱动基因的差异提示肺转移与肝转移患者应该分而治之，以实现患者最大化生存获益。Abstract: Objective To explore the clinical and genomic characterization of different visceral metastatic patterns in prostate cancer patients.Methods We leveraged a prospective clinic-genomic cohort of 859 prostate cancer patients to identify 75 patients with visceral metastasis. Among them, there were 41 patients with lung metastasis and 34 patients with liver metastasis, respectively. All patients have available clinical and genomic data. We analyzed the association between visceral metastatic patterns and clinical-genomic characterization.Results The incidence of lung metastasis and liver metastasis in mCSPC were 9.3% and 3.0%, respectively, whereas the incidence in mCRPC were 6.2% and 9.1%, respectively. There was no significant association between metastatic patterns and clinical-genomic characterization. Notably, patients with liver metastasis were enriched with AR gain (38.2% vs 12.2%, P= 0.013), CCND1 gain (20.6% vs 2.4%, P = 0.02), PTEN loss (20.6% vs 2.4%, P= 0.02), and BRCA2 loss (11.8% vs 0%, P = 0.04).Conclusion More attention should be paid to lung metastasis for patients in mCSPC, while more attention should be paid to liver metastasis for patients in mCRPC. The difference in molecular basis indicated diverse treatment strategies should be adopted for patients with different visceral metastasis.
-
Key words:
- prostate cancer /
- visceral metastasis /
- genomic profiling
-
-
表 1 内脏转移在不同临床阶段的发生率
例(%) 疾病阶段 肺转移(41例) 肝转移(34例) 无内脏转移(468例) 转移性去势敏感性 19(6.2) 28(9.1) 261(84.7) 转移性去势抵抗性 22(9.3) 7(3.0) 207(87.7) 
下载: 导出CSV
表 2 不同内脏转移模式前列腺癌患者的临床特征比较
例(%)，M(P25，P75) 临床特征 肺转移(41例) 肝转移(34例) P值 发病年龄/岁 66(60~71) 63.5(60.3~68.3) 0.600 检测年龄/岁 68(65~74) 68.5(65~75) 0.700 确诊时PSA/(ng·mL-1) 100.0(52.6~200.0) 77.2(34.0~205.9) 0.600 检测时PSA/(ng·mL-1) 67.9(5.5~127.0) 18.7(0.4~149.0) 0.500 转移时机 0.800 初诊 31(75.6) 24(70.6) 复发 10(24.4) 10(29.4) Gleason评分 1.000 6~7 4(9.8) 4(11.8) 8~10 37(90.2) 30(88.2) 药物治疗史 0.052 阿比特龙 14(34.1) 20(58.8) 多西他赛 9(22.0) 10(29.4) 阿比特龙和多西他赛 7(17.1) 8(23.5) 不详 22(53.7) 9(26.5) T分期 0.600 T2 15(36.6) 11(32.4) T3 20(48.8) 20(58.8) T4 6(14.6) 3(8.8) N分期 N0 16(39.0) 14(41.2) 1.000 N1 25(61.0) 20(58.8)
下载: 导出CSV
-
[1] Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J, 2022, 135(5): 584-590. doi: 10.1097/CM9.0000000000002108
[2] Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA, 2021, 71(3): 209-249.
[3] Halabi S, Kelly WK, Ma H, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer[J]. J Clin Oncol, 2016, 34(14): 1652-1659. doi: 10.1200/JCO.2015.65.7270
[4] Pond GR, Sonpavde G, de Wit R, et al. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer[J]. Eur Urol, 2014, 65(1): 3-6. doi: 10.1016/j.eururo.2013.09.024
[5] Chakravarty D, Gao J, Phillips S, et al. OncoKB: A precision oncology knowledge base[J]. JCO Precision Oncol, 2017, 1: PO. 17.00011.
[6] Landrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to variant interpretations and supporting evidence[J]. Nucleic Acids Res, 2018, 46(D1): D1062-D1067. doi: 10.1093/nar/gkx1153
[7] Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer[J]. Nucleic Acids Res, 2019, 47(D1): D941-D947. doi: 10.1093/nar/gky1015
[8] Viswanathan SR, Ha G, Hoff AM, et al. Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing[J]. Cell, 2018, 174(2): 433-447. e19. doi: 10.1016/j.cell.2018.05.036
[9] ICGC Prostate UK Group, Gundem G, Van Loo P, et al. The evolutionary history of lethal metastatic prostate cancer[J]. Nature, 2015, 520(7547): 353-357. doi: 10.1038/nature14347
[10] Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer[J]. Cell, 2015, 161(5): 1215-1228. doi: 10.1016/j.cell.2015.05.001
[11] Quigley DA, Dang HX, Zhao SG, et al. Genomic hallmarks and structural variation in metastatic prostate cancer[J]. Cell, 2018, 174(3): 758-769. e9. doi: 10.1016/j.cell.2018.06.039
[12] Incidences of visceral metastases from prostate cancer increase after progression of castration-resistant status[J]. J Clin Oncol, 2022-08-29. https://ascopubs.org/doi/10.1200/JCO.2018.36.6_suppl.291.
[13] Nguyen B, Fong C, Luthra A, et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25, 000 patients[J]. Cell, 2021, 11: 112. doi: 10.3390/cells11010112
[14] Paschalis A, Sheehan B, Riisnaes R, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer[J]. Eur Urol, 2019, 76(4): 469-478. doi: 10.1016/j.eururo.2019.06.030
[15] Additional local therapy for liver metastases in patients with metastatic castration-resistant prostate cancer receiving systemic PSMA-targeted therapy[J]. J Nucl Med, 2022-08-29. https://jnm.snmjournals.org/content/61/5/723.
-